A recurring source of confusion is that bone grafts and biomaterials are often discussed as though they share a single remodelling timeline. The literature does not support that simplification. Much of the confusion starts when presence, disappearance, incorporation, and structural performance are treated as though they describe the same process.
Summary
Bone grafts and biomaterials do not follow one common time-course after implantation.
Calcium sulphate typically shows rapid loss over weeks to months, while hydroxyapatite-rich materials and bioactive glass often remain visible for prolonged periods.
Some composite materials change in phases rather than along a single present-to-absent timeline.
Structural retention, interface incorporation, and mechanical success are related but distinct observations.
Broad category labels such as calcium phosphate are often too imprecise to support one timeline.
Why This Matters
Time-dependent material behaviour is one of the clearest differences between grafts and graft substitutes, yet it is often flattened into generic language such as resorption, integration, or replacement. That creates problems because the same follow-up finding can sit within very different expected trajectories depending on material class. A rapidly resorbing filler, a slowly persistent ceramic, a structural allograft, and a non-resorbable cement such as polymethylmethacrylate (PMMA) do not raise the same questions when they remain present or change over time.
The consequences are not theoretical. In a recent series of precontoured cancellous allograft wedges used in foot and ankle surgery, the authors reported an overall radiographic complication rate of 10% and specifically cautioned readers about the risks of resorption and nonunion. In a randomised cervical fusion study, coralline hydroxyapatite grafts fragmented in 89% of cases and showed significant settling more often than autograft. These are very different adverse patterns, but both show why temporal behaviour cannot be reduced to whether a material is still visible at follow-up (Boden, 2025; McConnell, 2003).
What the Evidence Shows
Three broad time-course patterns recur across the literature:
rapid loss
staged or mixed change
prolonged persistence or structural retention
The clearest fast-loss pattern is calcium sulphate. Clinical series describe substantial loss over weeks to a few months rather than prolonged structural persistence. In one comparative tumour surgery series, injectable calcium sulphate was reported as a resorbable graft material with radiographic disappearance within three months in almost all cases. A separate prospective study likewise described relatively rapid resorption, with clinical and radiographic outcomes improving over subsequent follow-up rather than the material remaining as a long-standing scaffold. Taken together, these studies support fast loss as a genuine class pattern rather than an occasional finding (Kim, 2011; Kumar, 2013).
That does not mean rapid loss and structural replacement occur on the same schedule. This is one of the most important distinctions in the literature. In calcium sulphate series, the material may disappear before the defect has fully consolidated, leaving a temporary interval in which the implanted filler has largely gone but structural restoration is still catching up. That mismatch is not universal, and it does not make rapid resorption undesirable in itself, but it does mean that disappearance and replacement should not be treated as interchangeable terms (Kim, 2011; Kumar, 2013).
Some materials change in phases rather than along a single curve. This pattern is especially clear in composites that combine a faster-dissolving phase with a more persistent mineral phase. Clinical follow-up in injectable calcium sulphate and hydroxyapatite composites has described early loss of radiographic contrast and volume from the more soluble component, followed by slower residual change and progressive bone infill over later months. In one prospective series, remodelling progressed across the first year rather than occurring as a simple early vanishing event. This staged behaviour sits between fast-resorbing fillers and long-persisting ceramics, and it is more accurately described as mixed change than as either rapid replacement or prolonged inert persistence (Iundusi, 2015; Kaczmarczyk, 2015).
Calcium phosphate is more heterogeneous than the label often suggests. The literature includes materials with very different structures, porosities, phase compositions, and implantation contexts, and their temporal behaviour is correspondingly heterogeneous. Experimental and clinical studies show that some calcium phosphate materials maintain volume for prolonged periods, some remodel gradually, and some show only partial substitution over long follow-up. Biphasic calcium phosphate granules in open-wedge high tibial osteotomy, for example, showed creeping substitution that remained incomplete beyond two years, while other calcium phosphate systems have shown a more active but still prolonged temporal response. The safest conclusion is not that calcium phosphate follows one timeline, but that the category is too broad unless narrowed to formulation and structure (Gauthier, 1999; Ozalay, 2009; Landeck, 2021; Garrido, 2011).
Long persistence is also a recurring and expected pattern in some classes. In porous hydroxyapatite wedges used in open-wedge high tibial osteotomy, radiodensity remained essentially stable from one to 36 months while bone ingrowth progressed at the interface. That pattern matters because it shows that prolonged radiographic presence may be expected in some classes even when healing is occurring. Persistence in this setting does not imply biological inactivity, but neither does bone ingrowth imply disappearance of the implanted material. The temporal pattern is one of retained mineral scaffold with interface maturation, not simple replacement (Koshino, 2001).
Hydroxyapatite-rich persistence also has limits, particularly in structural applications. In a prospective randomised cervical fusion study, coralline hydroxyapatite grafts achieved fusion rates comparable to autograft, but the grafts fragmented far more often and settled more frequently. That is an important reminder that prolonged presence, interface incorporation, and structural durability are not the same observation. A material may remain present and still behave poorly under the mechanical conditions imposed on it (McConnell, 2003).
Bioactive glass shows another form of prolonged persistence. Clinical follow-up and review data support a pattern of retention with interface bonding rather than rapid disappearance. In tibial plateau fracture augmentation, granules remained identifiable over follow-up while clinical and radiographic outcomes were acceptable. Review-level synthesis across orthopaedic use cases likewise describes long-lasting remnants in some settings, particularly in larger defects, together with a characteristic bone-contact behaviour rather than a simple present-to-absent sequence. For standard orthopaedic bioactive glass compositions, the literature supports slow change with interface maturation more strongly than complete early resorption (Heikkilä, 2011; van Gestel, 2015).
Structural allograft follows a different temporal logic again. It is not best understood through the language of resorption tempo, because its role is usually to retain structural presence while incorporation occurs gradually at the host-graft junction. In revision arthroplasty and related reconstructive settings, successful cases show persistent graft presence with progressive junctional union rather than disappearance of the graft as a whole. Failures, by contrast, are often expressed through nonunion at the interface, focal resorption, lucency, fracture, or later loss of correction. That makes structural allograft an important example of why retained presence and biological success cannot be collapsed into one measure (Clatworthy, 2001; Park, 2018; Chuang, 2022; Boden, 2025).
Taken together, the literature points to a simple conclusion: structural retention, interface incorporation, and adverse change are different questions. A material may remain visible for years and still be behaving as expected. A material may disappear quickly without proving that mature structural bone has formed. A graft-host junction may unite while the graft itself remains recognisable. A construct may fragment or settle despite apparent incorporation. These are not contradictions. They are different temporal patterns, and the literature becomes much easier to read once those categories are separated.
Polymethylmethacrylate (PMMA) provides a useful contrast because it is intended to remain rather than to be replaced by host bone. For that reason, its time-dependent behaviour is not discussed in terms of resorption or remodelling, but in terms of persistence, mechanical integrity, lucency, loosening, debris, and, where relevant, antibiotic release. It helps define the edge of the time-course map by showing that not all bone void fillers or implanted materials are expected to move towards disappearance or biological replacement over time (van Vugt, 2019; Steadman, 2023).
Common Pitfalls
Several recurring pitfalls make this topic harder to interpret than it needs to be. One is to treat synthetic substitutes as though they share a common timeline after implantation. The literature does not support that. Rapidly resorbing calcium sulphate, staged composites, persistent hydroxyapatite-rich materials, bioactive glass, structural allograft, and polymethylmethacrylate (PMMA) do not follow the same temporal pattern.
Another pitfall is to collapse different observations into one conclusion. Material persistence, radiographic visibility, interface incorporation, and structural performance are related, but they are not interchangeable. A material may remain present and still be behaving as expected. A material may disappear without proving that structurally useful bone has already formed. A graft-host junction may unite while the graft itself remains recognisable. A construct may fragment or settle despite apparent incorporation.
Imaging belongs in this picture, but only as one way of observing change over time. Persistent opacity may reflect retained scaffold, expected structural retention, or a mixture of material and new bone. Reduced visibility may reflect dissolution of a more soluble phase, loss of radiographic contrast, or true material loss. Those findings become more meaningful only when they are read in the context of material class and time-course.
Closing Note
The literature does not support one generic remodelling timeline after implantation. It supports several distinct time-course patterns, and those patterns differ materially across classes. Some fillers disappear quickly. Some composites change in phases. Some mineral scaffolds persist for prolonged intervals. Structural allograft is judged mainly through retention and junctional incorporation. Polymethylmethacrylate (PMMA) persists by design. Much of the confusion around bone grafts and biomaterials begins when those trajectories are collapsed into one language of integration, resorption, or replacement.
References
Boden AL, El Masry S, DiGiovanni GM, Demetracopoulos CA, Cody EA. Incidence of Complications With Precontoured Allograft Wedges in Foot and Ankle Surgery. Foot Ankle Int. 2025;46(1):29-36. doi:10.1177/10711007241294070.
Chuang CA, Lee SH, Chang CH, Hu CC, Shih HN, Ueng SWN, Chang Y. Application of structural allogenous bone graft in two-stage exchange arthroplasty for knee periprosthetic joint infection: a case control study. BMC Musculoskelet Disord. 2022;23(1):325. doi:10.1186/s12891-022-05228-6.
Clatworthy MG, Ballance J, Brick GW, Chandler HP, Gross AE. The use of structural allograft for uncontained defects in revision total knee arthroplasty. A minimum five-year review. J Bone Joint Surg Am. 2001;83(3):404-411. doi:10.2106/00004623-200103000-00013.
Garrido CA, Garrido F, Hernández D, et al. Biphasic calcium phosphate bioceramics for orthopaedic reconstructions: clinical outcomes. Int J Biomater. 2011;2011:129727. doi:10.1155/2011/129727.
Gauthier O, Bouler JM, Weiss P, Bosco J, Daculsi G, Aguado E. Kinetic study of bone ingrowth and ceramic resorption associated with the implantation of different injectable calcium-phosphate bone substitutes. J Biomed Mater Res. 1999;47(1):28-35. doi:10.1002/(SICI)1097-4636(199910)47:1<28::AID-JBM4>3.0.CO;2-P.
Heikkilä JT, Kukkonen J, Aho AJ, Moisander S, Kyyrönen T, Mattila K. Bioactive glass granules: a suitable bone substitute material in the operative treatment of depressed lateral tibial plateau fractures: a prospective, randomized 1 year follow-up study. J Mater Sci Mater Med. 2011;22(4):1073-1080. doi:10.1007/s10856-011-4272-0.
Iundusi R, Gasbarra E, D'Arienzo M, Piccioli A, Tarantino U. Augmentation of tibial plateau fractures with an injectable bone substitute: CERAMENT™. Three year follow-up from a prospective study. BMC Musculoskelet Disord. 2015;16:115. doi:10.1186/s12891-015-0574-6.
Kaczmarczyk J, Sowinski P, Goch M, Katulska K. Complete twelve month bone remodeling with a bi-phasic injectable bone substitute in benign bone tumors: a prospective pilot study. BMC Musculoskelet Disord. 2015;16:369. doi:10.1186/s12891-015-0828-3.
Kim JH, Oh JH, Han I, Kim HS, Chung SW. Grafting using injectable calcium sulfate in bone tumor surgery: comparison with demineralized bone matrix-based grafting. Clin Orthop Surg. 2011;3(3):191-201. doi:10.4055/cios.2011.3.3.191.
Koshino T, Murase T, Takagi T, Saito T. New bone formation around porous hydroxyapatite wedge implanted in opening wedge high tibial osteotomy in patients with osteoarthritis. Biomaterials. 2001;22(12):1579-1582. doi:10.1016/S0142-9612(00)00318-5.
Kumar YC, Nalini KB, Menon J, Patro DK, Banerji BH. Calcium sulfate as bone graft substitute in the treatment of osseous bone defects, a prospective study. J Clin Diagn Res. 2013;7(12):2926-2928. doi:10.7860/JCDR/2013/6404.3791.
Landeck JT, Walsh WR, Oliver RA, Wang T, Gordon MR, Ahn E, White CD. Temporal response of an injectable calcium phosphate material in a critical size defect. J Orthop Surg Res. 2021;16(1):534. doi:10.1186/s13018-021-02651-8.
McConnell JR, Freeman BJC, Debnath UK, Grevitt MP, Prince HG, Webb JK. A prospective randomized comparison of coralline hydroxyapatite with autograft in cervical interbody fusion. Spine (Phila Pa 1976). 2003;28(4):317-323. doi:10.1097/01.BRS.0000048503.51956.E1.
Ozalay M, Sahin O, Akpinar S, Ozkoc G, Cinar M, Cesur N. Remodeling potentials of biphasic calcium phosphate granules in open wedge high tibial osteotomy. Arch Orthop Trauma Surg. 2009;129(6):747-752. doi:10.1007/s00402-008-0781-9.
Park JS, Moon KH. Medium- to Long-term Results of Strut Allografts Treating Periprosthetic Bone Defects. Hip Pelvis. 2018;30(1):23-28. doi:10.5371/hp.2018.30.1.23.
Steadman W, Chapman PR, Schuetz M, Schmutz B, Trampuz A, Tetsworth K. Local Antibiotic Delivery Options in Prosthetic Joint Infection. Antibiotics (Basel). 2023;12(4):752. doi:10.3390/antibiotics12040752.
van Gestel NAP, Geurts J, Hulsen DJW, van Rietbergen B, Hofmann S, Arts JJ. Clinical Applications of S53P4 Bioactive Glass in Bone Healing and Osteomyelitic Treatment: A Literature Review. Biomed Res Int. 2015;2015:684826. doi:10.1155/2015/684826.
van Vugt TAG, Arts JJ, Geurts JAP. Antibiotic-Loaded Polymethylmethacrylate Beads and Spacers in Treatment of Orthopedic Infections and the Role of Biofilm Formation. Front Microbiol. 2019;10:1626. doi:10.3389/fmicb.2019.01626.